AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03973632 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SH-1028 Tablets
Description: 200mg of SH-1028 Tablets, orally once every cycle.
Study NCT02033291 — intervention group
Intervention type: PROCEDURE
Intervention: Dynamic contrast enhanced Brain MRI
Description: DCE-MRI is used to quantify the BBB permeability
Study NCT02814812 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: CT scan
Study NCT01902654 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular risk factors diagnoses collection.
Description: We look over patient medical record and we collect the diagnoses associated with cardiovascular risk factor as hypertension, obesity, dislipidemia and diabetes.
Study NCT01902654 — intervention group
Intervention type: OTHER
Intervention: History of cardiovascular disease
Description: In all patient we collect the history of cardiovascular disease.
Study NCT01902654 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular risk factors association
Description: We have defined two groups according to grouping of none, 1 or 2 cardiovascular risk factors or 3 or more.
Study NCT01822431 — intervention group
Intervention type: RADIATION
Intervention: metaiodobenzylguanidine scintigraphy
Study NCT00443365 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Mitral valve repair
Description: mitral valve annuloplasty
Study NCT03861234 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 836880
Description: Solution for Intravitreal (IVT) injection
Study NCT02408718 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Assistive Device Training
Description: Six-week training program on the proper use of the subject's assistive device (eg. cane, walker, etc).
Study NCT01051531 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Description: One intramuscular (IM) injection of paliperidone palmitate 150 mg equivalent (eq.) on Day 1, 100 mg eq. on Day 8, and 75 mg eq. on Day 38. Thereafter, one IM injection of paliperidone palmitate 50, 75, 100, or 150 mg eq. once monthly. Doses may be adjusted every 30 days per the clinician's judgment within the dose range of 50 to 150 mg eq.
Study NCT00780143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plitidepsin plus Cytarabine
Description: Plitidepsin 0.54 mg /m2 (initial dose)daily x 5 one hour infusion every 3 weeks plus Cytarabine 1 g/m2 daily for 5 days.
Study NCT00725192 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 12 sessions of Cognitive Processing Therapy.
Study NCT00725192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy
Description: Clients will receive between 12 sessions of Cognitive Processing Therapy.
Study NCT00725192 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Hypnosis
Description: PArticipants will receive 3 sessions of hypnosis to specifically target sleep impairment.
Study NCT04410848 — intervention group
Intervention type: OTHER
Intervention: To determine the diagnostic of Choledocholithiasis with symbolic regression model
Description: To determine the diagnostic of Choledocholithiasis with symbolic regression model
Study NCT03076060 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Ketogenic diet
Description: Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the KD.
Study NCT03076060 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Sham Diet
Description: Two different kind of diet, a Very Low Calories Ketogenic Diet (KD) and a sham weight-loss diet (SD), will be consecutively administered in each patient recruited in the study for one month. To avoid the bias of different caloric intake, SD group will undergo to a non-ketogenic Very Low Calories Diet . Randomly patients will start with KD or SD.~Patients assigned to this arm will follow the SD.
Study NCT00911196 — intervention group
Intervention type: OTHER
Intervention: Retrospective analysis of already archived samples
Description: Analysis using RNA extracted from tissue samples already archived; Analysis by Fluorescent in situ hybridization (FISH) using tissue samples already archived.
Study NCT03088930 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Crizotinib is an oral receptor tyrosine kinase inhibitor of ALK, Hepatocyte Growth Factor Receptor (HGFR, c-Met), and ROS1 (c-ros). Crizotinib will be given as a neoadjuvant therapy before surgical resection. The recommended dose of crizotinib is 250mg orally. Participants on this trial will receive this dose, unless dose modification is necessary.
Study NCT03296748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: trans-obturator tape inside-out usingsoft tapes.
Description: trans-obturator tape inside-out soft tapes is applied under spinal anesthesia. After the procedure, the vaginal gauze packing and Foley catheter were removed on the morning of the next day.
Study NCT03296748 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: anterior colporraphy
Study NCT04743336 — intervention group
Intervention type: OTHER
Intervention: Measuring pocket depth
Description: Probing pocket depth (PPD = distance between gingival margin and bottom of the periodontal pocket)were evaluated in each patient. All periodontal measurements were recorded at six sites around each tooth by a periodontal probe excluding third molar
Study NCT03515733 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04995274
Description: PF-04995274 tablets
Study NCT02807155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Empowerment Program
Description: Participants will receive the 1-year transition empowerment program/curriculum (TEP-CG) alone.
Study NCT05914896 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HighOsmo
Description: This group received a priming solution with high osmolality
Study NCT04036955 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: INFOSA-DEM
Description: Caregivers in the intervention group received the INFOSA-DEM programme, together with usual care provided by the participating centres, while caregivers in the CG received usual care in the centres where the follow-up was carried out.
Study NCT01920191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IMA 950
Study NCT01920191 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Poly ICLC
Study NCT01920191 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Immunomonitoring
Description: Blood samples, DTH analysis
Study NCT01404585 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablets, Oral, 0 mg, twice daily, 12 weeks
Study NCT01404585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-817399
Description: Tablets, Oral, 200 mg, twice daily, 12 weeks
Study NCT01404585 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-817399
Description: Tablets, Oral, 400mg, twice daily, 12 weeks
Study NCT02807155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Transition Empowerment Program (TEP) + Diabetes Wellness Council (DWC)
Description: Participants will receive the identical 1-year Transition Empowerment Program, plus the innovative wellness-based group process (council).
Study NCT02807155 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Transition Empowement Program Access
Description: Participants assigned to an outside medical home would be followed according to the clinical needs as assessed by their medical provider. They would be given access to the TEP website curriculum, but would not participate in other aspects of the 1-year TEP.
Study NCT01784744 — intervention group
Intervention type: OTHER
Intervention: Hydroworx Pool at 98 degrees Fahrenheit
Study NCT01784744 — intervention group
Intervention type: OTHER
Intervention: Hydroworx Pool at 102 degrees Fahrenheit
Study NCT02099123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Atorvastatin 20 mg tablet
Study NCT02099123 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Atorvastatin)
Description: Inactive pill manufactured to mimic Atorvastatin 20 mg tablet
Study NCT02786446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel,
Description: 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Study NCT02786446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Naproxen Sodium
Description: Tab Naproxen sadium 550 mg per oral will be given to patients 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Study NCT02786446 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine gel and Naproxen Sodium
Description: Tab Naproxen sodium 550 mg per oral will be given to patients 45 minutes before ESWL and 2% lidocain gel will be applied to coresponding lumber area 30 minutes before ESWL for renal stones. Maximum of 4000 shock waves will be delivered. Rescue analgesia will be given as intravenous nalbuphine if patient demanded. Pain score is measured with visual analogue pain score from 1 to 10 after completion of procedure if patient donot needed rescue analgesia and during procedure just before giving rescue analgesia in those who demanded it.
Study NCT04121377 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resistance training
Description: Weekly sessions introducing resistance exercises and monitoring the patients acceptability. The exercises are isometric contractions, seated heel-rise and elastic band. The patient register the amount of exercise in a home exercise journal. To protect the tendon while doing range of motion of the foot, dorsiflexion is restricted beyond neutral (0 degrees of dorsiflexion). The load on the strength exercises will progress from isometric contraction without external load to strengthening exercises with 10-20 RM (RM: Repetition Maximum). Each strength exercise can progress with added weight or stronger elastic band. The Borg scale is used to guide the patient to progress or regress the load in each exercise. The recommended level being easy to hard (2-5/10). It is emphasised that the exercises must not cause sudden or severe pain in the tendon, but muscle soreness is to be expected.
Study NCT03809416 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Lasers
Description: Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
Study NCT03809416 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Lasers
Description: Fractional carbon dioxide laser will be applied only over spots of deep post-acne scars, while Erbium: Glass will be applied all over face except to the two predetermined spots, i.e. control and another spot where NSS will be injected.
Study NCT03809416 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Platelets Rich Plasma
Description: Platelet Rich Plasma (PRP) will be prepared from autologous blood collection in a syringe prefilled with anticoagulant solution followed by centrifugation then adding calcium gluconate 10% for induction of platelet activation. Activated PRP will be injected for all carbon dioxide laser spots in each patient immediately after each laser session except for two predetermined spots, i.e. control and sham comparator, which will be injected by normal saline solution (NSS).
Study NCT03809416 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: SHAM_COMPARATOR
Intervention: Lasers plus Normal Saline Solution
Description: Normal Saline Solution will be injected only in one spot after combined lasers resufacing to act as sham comparator compared to the other spot of Lasers plus PRP injection
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 653048 BS
Study NCT05815940 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Application
Description: a mobile application was developed that can be used by children with urinary incontinence and their parents.
Study NCT01456468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral all-trans retinoic acid (ATRA)
Description: The subjects will continue to take their current dose of UDCA (15 mg/kg/day), as per ongoing clinical care, and need to be on a stable dose of UDCA for at least six months prior to enrollment.~The specific intervention is the addition of daily oral ATRA (45 mg/m\^2) divided into 2 doses. To increase adherence to the dosing regimen, the drug will be compounded by the Research Pharmacies of Yale and Mayo into 2 formulations (30 mg and 40 mg capsules), and an Investigational New Drug (IND) permit was obtained for this process.
Study NCT02634229 — intervention group
Intervention type: GENETIC
Intervention: blood sample
Study NCT01458652 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kremezin
Description: Kremezin is an oral adsorbent, 9g/day in treatment arm
Study NCT00987220 — intervention group
Intervention type: DRUG
Intervention: Placebo
Description: Oral
Study NCT00987220 — intervention group
Intervention type: DRUG
Intervention: donepezil (Aricept)
Description: 5mg oral
Study NCT01479673 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Indirect Calorimetry measurement of Resting Energy Expenditure .
Description: Patients in this group will receive enteral nutrition/parenteral nutrition or combination of enteral and parenteral nutrition according to the individual energy requirements calculated by Indirect Calorimetry.
Study NCT01785550 — intervention group
Intervention type: OTHER
Intervention: Ultrasound of nerve and muscle
Description: Ultrasound of 6 muscles and 2 nerves will be performed.
Study NCT00878774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: ToleroMune Ragweed
Description: ToleroMune Ragweed dose 1x4 administrations 2 weeks apart
Study NCT00878774 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo comparator, 1x4 administrations 2 weeks apart
Study NCT01993654 — intervention group
Intervention type: PROCEDURE
Intervention: HRT III with Non-Contact Cornea Rostock Module
Description: Confocal imaging of the conjunctival lesion
Study NCT02903966 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GSK2982772
Description: GSK2982772 is available as a 30 mg white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
Study NCT02903966 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is available as a white to almost white, round film coated tablet which will be administered as two tablets three times a day as directed.
Study NCT02996240 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 FFA
Description: Omega-3 Free Fatty Acid will be given as a fish oil in a capsule.
Study NCT01929278 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CT Gel (clindamycin 1% and tretinoin 0.025%)
Description: Three CT Gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures.
Study NCT01929278 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle gel patch
Description: Three vehicle gel patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 2. Vehicle gel contained the identical ingredients and packaging as CT Gel but without the active ingredients. All vehicle gel used during the study was from batch ZLU C.
Study NCT01929278 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Blank patch
Description: Three blank patches were concurrently applied to designated test sites by trained technicians and held in place with hypoallergenic tape. Patches were prepared no longer than 30 minutes prior to application to study subjects. A minimum distance of ¾ of an inch from patch pad to patch pad was maintained on a subject's back. Approximately 24 ±1 hours after patch application, test patches were removed by trained technicians. Patch sites were evaluated for signs of inflammation according to procedures. 3. Occlusive patches consisted of a non-woven cotton pad (Webril \[approximately 2 cm x 2 cm\]) covered and secured on all sides by an occlusive hypoallergenic tape (approximately 4 cm x 4 cm).
Study NCT00822991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: CE-US (Sonazoid™)
Description: screening by CE-US using Sonazoid(TM) in the postvascular phase every 3-5 months
Study NCT00822991 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: B-mode US
Description: screening by conventional B-mode US every 3-5 months
Study NCT01113983 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve implantation
Description: Transcatheter aortic valve implantation via transapical and transfemoral approach
Study NCT03684395 — intervention group
Intervention type: DRUG
Intervention: DOACs: Rivaroxaban, Dabigatran, Apixaban
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Study NCT03684395 — intervention group
Intervention type: DRUG
Intervention: Standard of care (Warfarin)
Description: Routinely collected clinical data (secondary data from patients with non-valvular atrial fibrillation in Sweden); no primary data collection
Study NCT02397278 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platelet rich plasma (PRP)
Description: Patient will receive 3 intra articular injections with autologous PRP in the affected knee and then follow conventional therapy.
Study NCT00844389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Near to infrared light retinal stimulation
Description: Patients will be stimulated with 660 nm light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
Study NCT00844389 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Green light stimulation
Description: Patients will be stimulated with 530 nm LED light frequency through a LED device. Patients will be stimulated daily for two minutes for a 6 month period.
Study NCT03444961 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CAREN system training
Description: CAREN allows Argus users to be trained and enhance their device usage in a safe, controlled, and standardized environment.
Study NCT00664872 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: proactive psychosocial intervention by care managers
Description: A case manager will be assigned to each of the participants in the intervention group. All case managers are psychologists. After discharge from the emergency department, the participants receive six sessions of proactive psychosocial intervention by their case manager over four months. Duration of each session is approximately 30 minutes. The intervention consists of telephone or face-to-face contacts with the case manager at scheduled intervals or when clinically necessary. If a patient declines medication therapy from the psychiatrist, case manager will provide psychotherapy using the model of cognitive-behavioural approach and problem-solving therapy. Case managers will receive backup and supervision by psychiatrist investigators and monthly supervision of therapy. Case managers will regularly monitor suicide risk, clinical status and provide follow-up.
Study NCT02224105 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone low
Study NCT00664872 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: case management
Study NCT04540601 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continuation of antiresorptives in relation to tooth extraction (surgical tooth removal)
Description: We want to investigate the importance of an antiresorptive drug holiday (bisphosphonate, denosumab) in relation to tooth extraction. The experimental intervention in this trial is drug continuation starting before tooth extraction with primary closure.~We simply ask the participating cancer patients to continue their high dose antiresorptive treatment for 4 months (intervention-period: 1 month pre-operative, 3 months post-operative) instead of taking a drug holiday.